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Abstract: Women are still at high risk of contracting the human immunodeficiency virus (HIV)
virus due to the lack of protection methods under their control, especially in sub-Saharan countries.
Polyelectrolyte multilayer smart vaginal films based on chitosan derivatives (chitosan lactate, chitosan
tartate, and chitosan citrate) and Eudragit® S100 were developed for the pH-sensitive release of
Tenofovir. Films were characterized through texture analysis and scanning electron microscopy
(SEM). Swelling and drug release studies were carried out in simulated vaginal fluid and a mixture
of simulated vaginal and seminal fluids. Ex vivo mucoadhesion was evaluated in bovine vaginal
mucosa. SEM micrographs revealed the formation of multilayer films. According to texture analysis,
chitosan citrate was the most flexible compared to chitosan tartrate and lactate. The swelling studies
showed a moderate water uptake (<300% in all cases), leading to the sustained release of Tenofovir
in simulated vaginal fluid (up to 120 h), which was accelerated in the simulated fluid mixture
(4–6 h). The films had high mucoadhesion in bovine vaginal mucosa. The multilayer films formed
by a mixture of chitosan citrate and Eudragit® S100 proved to be the most promising, with zero
toxicity, excellent mechanical properties, moderate swelling (<100%), high mucoadhesion capacity,
and Tenofovir release of 120 h and 4 h in vaginal fluid and the simulated fluid mixture respectively.
Keywords: chitosan lactate; chitosan tartrate; chitosan citrate; Eudragit® S100; layer-by-layer
film; mucoadhesive film; Tenofovir controlled release; pH responsive release; vaginal preexposure
prophylaxis; HIV sexual transmission
1. Introduction
Acquired immunodeficiency syndrome (AIDS) is still the leading cause of death among young
women. According to United Nations Joint Programme on HIV/AIDS (UNAIDS), 460 adolescent
women contract human immunodeficiency virus (HIV) each day and 350 women of the same age
group die weekly of AIDS-related complications. In fact, almost 80% of people infected with HIV in
the 10–19 age group in sub-Saharan Africa in 2017 were women [1]. Unfortunately, women in these
countries do not benefit from options to prevent the sexual transmission of HIV such as condoms, due
to gender differences which prevent them from negotiating with their sexual partners. This highlights
the need to develop prevention systems that women can initiate without their partner’s consent [2].
In this scenario, topical preexposure prophylaxis (PrEP) with antiretroviral drugs is one option to
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prevent the sexual transmission of HIV, since they can be applied in the vagina and serve as a method
of protection that can be controlled by women themselves, thus empowering them in the fight against
HIV-1 infection without the consent of their sexual partner [3].
Tenofovir (TFV) is an ideal candidate for use as a topical microbicide for preventing the sexual
transmission of HIV due to its efficacy, long half-life, and safety profile [4]. Clinical trials have been
carried out with this drug in different dosage forms such as rings [5] and gels [6].
However, adherence is central to PrEP effectiveness, and it is essential to develop products that
are easy to use and support high adherence [7]. Vaginal films are emerging as a promising option
among the pharmaceutical dosage forms in developmental stages, as they are preferred over other
dosage forms due to their advantages of portability, storage and handling, and also ensure comfort
and ease of insertion [8,9]. Fast dissolving films based on TFV have been produced and show lower
leakage and similar vaginal drug concentrations to those obtained with vaginal gels for pericoital
administration. Nevertheless, sustained release formulations must be developed to provide lasting
protection to women [7].
One approach to obtaining films for the sustained release of drugs is the use of the layer-by-layer
(LbL) technique, which produces films composed of two or more layers of different polymers. This offers
great versatility, since it combines the properties of the constituent polymers of each layer [10].
For instance, the combination of a highly mucoadhesive polymer to increase vaginal retention [11]
with another polymer capable of modulating the release of the drug [12] can achieve effective and
long-lasting drug release in the vaginal mucosa. The combination of polyanionic polymeric layers with
polycationic polymeric layers by means of this technique also produces polyelectrolyte multilayers
(PEM) [13,14], with the advantage that these polymers have a pH-dependent behaviour [15,16]. This is
of great interest when developing formulations for the prevention of sexual transmission of HIV,
since accelerating vaginal drug release at the time of ejaculation can increase the effectiveness of the
protection [17].
Among the polycationic polymers that are being explored, chitosan is a copolymer composed of
β(1→4)-linked 2-acetamido-2-deoxy-β-d-glucopyranose (N-acetylglucosamine) and α(1→4)-linked
2-amino-2-deoxy-β-d-glucospyranose (glucosamine). Chitosan has been widely explored in the
development of several pharmaceutical dosage forms such as tablets [11,18], hydrogels [19] and
bigels [17], and attempts have recently been made to develop chitosan-based films as drug delivery
systems [20,21]. Chitosan has mucoadhesive properties and antimicrobial activity; is from a renewable
source and is completely devoid of toxicity, and has many applications in the pharmaceutical industry
such as wound dressing and drug delivery systems [22,23]. This polymer has a pH-dependent solubility
due to the presence of the amine groups in its structure [24], and the protonation of these groups in
dilute acids allows the gelation of the polymer. Acetic acid is widely used among the various acids
applied for the gelation of chitosan [25], although its strong and unpleasant smell induces rejection
when applying the formulations [26]. For this reason, other acids are beginning to be used that allow
the gelation of chitosan with better organoleptic properties, such as lactic acid [26], tartaric acid [27],
and citric acid [28]. It has even been proven that the dilute acid used to dissolve the chitosan can
condition the polymer’s properties [29].
In order to improve its properties, it possible to add suitable fillers [30,31] or combine it with
different polymers such as hypromellose [32], sodium alginate [33], pectin [18], poly(vinyl alcohol) [34]
and different types of Eudragit® [35,36], among which it is particularly worth highlighting Eudragit®
S100 (ES100), a polyanionic copolymer derived from metacrylic acid and methyl metacrylate. It is
non-soluble in acids and water but soluble in dissolutions with a pH of over 7 [37]. This behaviour
makes it an interesting candidate for the development of pH-sensitive drug delivery systems for oral,
ocular, vaginal and topical administration [38]. Mixtures of chitosan and ES100 have been explored
with promising results, due to their ability to form polyelectrolyte complexes [39].
Although nowadays films are a promising tool for vaginal administration, the development of
controlled release films is a field yet to be explored. Furthermore, the use of pH-sensitive polymers may
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allow obtaining novel drug delivery systems for the prevention of sexually transmitted diseases [40].
Against this backdrop, the aim of this study is to develop PEM vaginal films based on optimized
chitosan derivatives and ES100 using the LbL technique and evaluate them through scanning electron
microscopy, texture analysis, swelling, ex vivo mucoadhesion and drug release tests and materials
citotoxicity. These films would allow a high mucoadhesion capacity due to the presence of the
chitosan-based layer, and a sustained release in the vaginal environment thanks to the ES100 layer.
After ejaculation during intercourse, the release of the drug would accelerate, thus maximizing the
effectiveness of the formulations in the prevention of the sexual transmission of HIV.
2. Results and Discussion
2.1. Characterization of Chitosan Gels
The results of the characterization of the gels are shown in Figure 1.
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Figure 1. Results of the characterization of the chitosan gels prepared with lactic acid (gChL), tartaric
acid (gChT) and citric acid (gChC) at different concentrations (0.25 M (a), 0.5 M (b) and 1 M (c)). (A) and
(B) show the texture analysis results (maximum penetration force (MPF) and maximum detachment
force (MDF) respectively). (C) shows the pH values obtained for the gels.
According to these data, all the gels had identical results for maximum penetration force (MPF,
Figure 1A) and maximum detachment force (MDF, Figure 1B), indicating that the consistency of chitosan
gels, represented by the MPF, is not modified by the acid used for its gelation. The adhesiveness of the
gel, represented by the MDF, is also equal in all the gels. These properties are therefore characteristic of
the polymer and are not modified by the acid. Previously published results show that pure water has
similar values of MPF and MDF (7.90 ± 00 g and 1.49 ± 0.07 g) [41], so at these concentrations, chitosan
gels have a similar consistency and adhesiveness to pure water. However, a comparison of the pH of
the different gels in Figure 1C reveals some differences. In all cases an increase in the acid concentration
leads to a decrease in the pH of the gel. The gels prepared with lactic acid show the highest values
of pH (≈2.5–4), while citric acid and tartaric acid generate more acid gels, with pH values in the
range of ≈2–3. According to the literature, the use of acidic substances in the vaginal environment
may be beneficial for the prevention of sexually transmitted infections [42,43]. These formulations
would therefore allow the acidification of the medium after administration, making them interesting
candidates for the development of formulations for the prevention of sexual transmission of HIV.
2.2. Chitosan Derivative-Based Films
2.2.1. Attenuated Total Reflection Fourier Transform Infrared (FTIR-ATR) Spectroscopy
Figure 2 shows the spectra obtained for the raw materials. In the spectrum corres onding to raw
chitosan, bands are observed at 1655 cm−1 and 1325 cm−1, corresponding to the C=O bond of amide I
and the N-H bond of amide III respectively. A band appears at 1585 cm−1, corresponding to the free
amine [44]. In the lactic acid spectrum, a peak can be observed at 1720 cm−1 corresponding to the
C=O bond of the acid group, and a band at 1210 cm−1 that can be attributed to the C-O carboxylic
acid bond [45]. In tartaric acid, the peak observed at 1720 cm−1 corresponds to the C=O bond of the
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carboxylic acid. Another peak at 1445 cm−1 corresponds to the O-H bond of the carboxylic groups.
The peaks at 1185 cm−1, 3328 cm−1 and 3400 cm−1 are also attributable to O-H links [46]. In the citric
acid spectrum, the peaks that appear around 1720 cm−1 are due to the C=O bonds of carboxylic acids.
A band corresponding to the O-H bond of carboxylic acids is observed at 1390 cm−1. The 3492 cm−1
peak is also attributable to free hydroxyls [47].
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Figure 2. Spectra obtained through FTIR-ATR for the raw materials used to manufacture the chitosan
derivative films.
The spectra corresponding to chitosan films prepared with different amounts of lactic acid (ChL-a,
ChL-b and ChL-c) are shown in Figure 3. All have a broad band between 1660–1475 cm−1, caused by
the overlapping of the chitosan amide (1655 cm−1) and the C=O bond corresponding to the amide
formed with lactic acid [48]. Since the carbonyl in the acid (1720 cm−1) changes to amide, a reduction
in the intensity of this peak can be seen in samples ChL-a and ChL-b. The peak is also observed to
decrease to 1210 cm−1, due to the replacement of hydroxyl in the formation of this amide (Scheme 1a).
When the amount of lactic acid in the film is increased (especially in ChL-c), esters form between the
lactic acid molecules, creating oligomers of polylactic acid (Scheme 1b) [48] and causing the intensity
of the band to increase at 1720 cm−1 due to the C=O bonds corresponding to the esters. The formation
of these esters is favoured by the high concentration of lactic acid, so this peak is more intense than
the peak attributable to the C=O of the amide. The band at 1210 cm−1 also increases, indicating the
presence of the C-O bond, which is absent in the amide but present in the ester [48].
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Scheme 1. Chemical reaction between chitosan and lactic acid. First, the carboxylic group of lactic
acid reacts with the amine group of chitosan, forming the corresponding amide (henceforth chitosan
lactate) (a). If there is an excess of lactic acid, the carboxylic groups of free molecules react with the free
hydroxyl of the lactic group in chitosan lactate, forming polylactate groups (b).
The spectra corresponding to chitosan films prepared with tartaric acid are shown in Figure 4.
A broad band appears between 1660 cm−1 and 1475 cm−1, ith two peaks attributable to the amide
group [49]. In ChT-a and ChT-b, the peak disappears at 1445 cm−1, corresponding to the O-H bond
of the carboxylic acid of the tartaric acid. Other peaks that disappear with the lowest proportions
of tartaric acid are 1185 cm−1, 3400 cm−1 and 3328 cm−1, which also indicates the replacement of
hydroxyls in tartaric acid and confirms the formation of the amide between chitosan and tartaric
acid (Scheme 2) [27]. The absence of these peaks corresponding to the O-H bonds of the carboxylic
acids indicates that all acid groups react with the chitosan amines, suggesting that tartaric acid acts as
a crosslinker of the chitosan chains. The peaks corresponding to O-H bonds (1445 cm−1, 1185 cm−1,
3328 cm−1, and 3400 cm−1) [46] reappear with the highest amount of tartaric acid (ChT-c), indicating
that not all the tartaric acid is used in the reaction at this proportion.
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Figure 4. Spectra obtained through FTIR for the films manufactured by solvent casting chitosan gels
prepared with differe t concentrations of tartaric acid: 0.25 M (ChT-a), 0.5 M (ChT-b) and 1 M (ChT-c).
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2.2.2. Appearance and Mechanical Properties 
The films made with chitosan derivatives were visually evaluated. The pliability and organoleptic 
characteristics of each batch are shown in Table 1. 
Scheme 2. Chemical reaction between chitosan and tartaric acid. The carboxylic groups of tartaric
acid react with the amine group of chitosan, forming the corresponding amide (henceforth chitosan
tartrate). The complete reaction with the two carboxylic groups in the molecule of tartaric acid leads to
the crosslinking of chitosan.
According to the spectra obtained for the chitosan films prepared with citric acid shown in Figure 5,
a wide band appears between 1660 cm−1 and 1475 cm−1, attributable to the formation of the amide
group [50]. The bands at 1390 cm−1 and 3492 cm−1 disappear in samples ChC-a and ChC-b due to
the replacement of all free carboxylic hydroxyls by the chitosan amines. This indicates that amide is
formed between chitosan and citric acid, and that citric acid acts as a crosslinker for chitosan chains
through an amide form d between both compounds (Scheme 3) [51]. The peak at 1390 cm−1 nd 3492
cm−1 reappear in the sample with the highest proportion of citric acid (ChC-c), suggesting that the
reaction with citric acid in these proportions is incomplete.
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Scheme 3. Chemical reaction between chitosan and citric acid. The carboxylic groups of citric
acid react with the amine group of chitosan, forming the corresponding amide (henceforth chitosan
citrate). The complete reaction with the three carboxylic groups in the citric acid molecule leads to the
crosslinking of chitosan.
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2.2.2. Appearance and Mechanical Properties
The films made with chitosan derivatives were visually evaluated. The pliability and organoleptic
characteristics of each batch are shown in Table 1.
Table 1. Characteristics observed by visual evaluation of films based on chitosan derivatives.
Batch Pliability Organoleptic Characteristics Comments
ChL-a
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cases the films prepared with the diluted acids at 0.5 M (CaL-b, ChT-b, and ChC-b) were more flexible 
than those obtain d with the diluted acids at 0.25 M (ChL-a, ChT-a, and ChC-a). 
2.2.3. Drug Release Assessment 
hitosan d rivative films prepa ed with the previously determin  optimal c nce tration of
diluted acids (ChL-b, Ch -b, ChC-b) were loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
ChC-TFV). The drug release profiles from these chitosan derivative-based films are shown in Figure 6. 
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Table 1. Characteristics observed by visual evaluation of films based on chitosan derivatives. 
Batch Pliability Organoleptic Ch racteristics Co ments 
ChL-a ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. Soft touch. 
Although somewhat flexible, it 
breaks if folded in half. 
ChL-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChL-c ✖ Homogeneous. Translucent, yellowish and shiny. Odourless. Sticky touch. 
The film can barely be handled 
due to it  stickiness. 
ChT-a ✔ Homogeneous. Translucent, yellowish and shiny. Odourl ss. Soft touch.  
ChT-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChT-c ✖ H terogeneous. Opaque, yellowish and matt. Odourless. Rough touch. 
Compl tely r gid, it breaks when 
even slight force is applied. 
ChC-a ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChC-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChC-c ✖ H terogeneous. Opaque, yellowish and matt. Odourl ss. Rough touch. 
Compl t ly r gid, it breaks when 
even light f rce is applied. 
✖: Unacc ptable; ✔: Acceptable; ✔: G od; ✔: Excellent. 
The mec anical properti s of t e sy t m ust b ak n into account w en developi  films for 
vagin l ad nist ati , as they c n d ter n  comfort nd acc ptab lity fo the tient and may even 
b rel te   the perf rma c  of the film once d inistered. In the cas  f C L- , the formati  of 
polyl ctic acid i  o pronounce t at t  film i  cky and becom s imp ssible to han le. ChT- n  ChC-
c films were ls  ob erve  to  rigi and irr gul r, hic  c n b  a tribu d to th ex ess of aci  during 
the reaction, as co rob ra ed by FTIR s u ies (Sec i n 2.1). Th  excess f t rtaric acid or cit ic acid stiffens 
the fil , as t ey are ol d ubst nces. These films were erefore disc r d from fur her studies. 
The comparison of e other films in terms of the acid us d for heir preparation revealed that 
the films with chitosan lactat  had the owest deforma ion capacity, while t e containing chitosan 
ta trate or chitosan citrate had a higher c pacity. This may be related to the ab lity of tartaric acid and 
citric acid t  ct as crosslinkers, possibly fac litating t e mob lity of the c itosan chains [52]. In all 
cases the films prepare  with the diluted acids at 0.5 M (CaL-b, ChT-b, and ChC-b) were more flexible 
than those obtain d with th  diluted acids at 0.25 M (ChL-a, ChT-a, and ChC-a). 
.2.3. Drug R lease Assessment 
Chitosan erivative films prepa ed with the previously d termined optimal c centration of 
diluted acids (ChL-b, ChT-b, ChC-b) were loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
ChC-TFV). The drug r lease profiles from these chitosan derivative-based films are shown in Figure 6. 
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Table 1. Characteri tics obs rved by visual ev l ati n of films based on chitosan derivatives. 
Batch Pliability Organoleptic Ch racteri tics Co ments 
ChL-a ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. S ft touch. 
Although somewhat flexible, it 
breaks if folded in half. 
ChL-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. S ft touch.  
ChL-c ✖ Homogeneous. Translucent, yellowish and shiny. Odourless. Sticky touch. 
The film can barely be handled 
due to it  stickiness. 
ChT-a ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. S ft touch.  
ChT-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. S ft touch.  
ChT-c ✖ H terogeneous. Opaqu , yellowish and m tt. Odourless. Rough touch. 
Comp tely r gid, it breaks when 
even slight force is applied. 
ChC-a ✔ Homogeneous. Translucent, yellowish d shiny. Odourless. S ft touch.  
ChC-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. S ft touch.  
ChC-c ✖ H terogeneous. Op qu , yellowish an  mat . Odourless. Rough touch. 
Comp t ly r gid, it breaks when 
even light f r e is applied.
✖: Unacceptable;✔: Acceptabl ; ✔: G d; ✔ ✔: Excelle t. 
The m c anic l proper ies of the sy te  ust b ak  in o a count when dev loping films or 
vaginal ad ini rati , as they c n d ter ne c mfort nd acc ptab l ty fo  the patient nd may even 
b related o th  performanc of the film once ad inistered. In the case f ChL- , the formati n of 
polyl cti cid i  so pronounced a  the film i  s cky and becom  impossible to handle. ChT- n  hC-
c s were als  ob rved to be rigid and irregul r, w i  can b  attribut d t  th x ess of aci  during 
the reaction, as c rrob ra d by FTIR s u ies (Sec i n 2.1). Th  xcess of t rtaric cid  cit ic ci  s iff ns 
the fil , as y are olid subst nces. Th e films were therefore discard d from fur her studie . 
The comparis n of t e ot er films in terms of the acid used for t ei  reparation rev aled hat 
the films wit chitosan l ctate had the owest deformation capacity, while th e ontaining chitosan 
a rate or chitosan ci rate h d a igher c paci y  This may e related to the ab lity of tari  acid and 
citri  acid to ct as crosslinkers, possibly fac litating t e mob lity of the chitosan chains [52]. In all 
cases the films repared wit  the diluted acids at 0.5 M (CaL-b, ChT-b, and hC-b) were mor  flexible 
than those obtain d wit  th  diluted acids at 0.25 M (ChL-a, ChT-a, and hC-a). 
.2.3. Drug R l ase A essment 
Chitosan erivative films repared wi  the previously d termined optimal co centration of 
diluted acids (ChL-b, ChT-b, hC-b) were loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
hC-TFV). The drug r l ase profiles from these chitosan derivative-based films are shown in Figure 6. 
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Table 1. Characteristics observed by visual evaluation of films based on chitosan derivatives. 
Batch Pliability Organoleptic Characteristics Comments 
-a ✔ . l t, ll i   i . l . ft t . 
Although somewhat flexible, it 
breaks if folded in half. 
-b ✔✔ . l , ll i   i . l . oft touch. 
L c ✖ . l t, ll i   i . l . ticky touch. 
The film can barely be handled 
due t its sti kiness.
-a ✔✔ . l t, ll i   i . l .  .  
-b ✔✔✔ omogeneous. Transl cent, yellowish and shiny. Odourless. Soft touch.  
-  ✖ eterogeneous. Opaq e, yellowish and mat . Odourless. Rough touch. 
Completely rigid, it breaks when 
even slight force is applied. 
-a ✔✔ . l t, ll i   i . l . ft t .  
-b ✔✔✔ omogeneous. Transl cent, yellowish and shiny. Odourless. Soft touch.  
ChC-c ✖ Heterogeneous. Opaque, yellowish and matt. Odourless. Rough touch. 
Completely rigid, it breaks when 
even slight force is applied. 
: Unacceptable; ✔: Accept ble; ✔✔: Good; ✔✔✔: Excellent. 
The mechanical properties of t e syst m us be taken into account when developing films for 
vaginal administration, as they can determine com ort and acceptabili y for the patient and may even
be re ated to the performanc  of the fi m once administered. In the case of ChL-c, the format on of
polylactic a id is so pronounced that the film is sticky and becomes impossibl to handle. ChT-c and ChC-
 films were also obse ved to be rigid and irregular, which can e attributed to he excess of acid during
the reaction, a corroborated by FTIR studies (Section 2.2.1). The excess of tartaric acid or citric acid stiffens
e film, as they are solid substanc s. The e films were therefore discar ed from further studies. 
The comparison of the other films in terms of the acid used for their preparation revealed that 
the films with chitosan lactate had the lowest deformation capacity, while those containing chitosan 
tartrate or chitosan citrate had a higher capacity. This may be related to the ability of tartaric acid and 
citric acid to act as crosslinkers, possibly facilitating the mobility of the chitosan chains [52]. In all 
cases the films prepared with the diluted acids at 0.5 M (CaL-b, ChT-b, and ChC-b) were more flexible 
than those obtained with the diluted acids at 0.25 M (ChL-a, ChT-a, and ChC-a). 
2.2.3. Drug Release Assessment 
Chit san d iv tive films prepar  with the previously d t rmi  optimal concent atio  of 
diluted aci s (ChL-b, C T-b, ChC-b) were lo ded with 30 g of FV (batches hL-TFV, ChT-TFV d 
ChC-TFV). The drug r lease profiles from these chitosan derivative-base  films are shown in Figure 6. 
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Table 1. Characteristics observed by visual eval ation of films bas d on chitosan derivatives. 
Batch Pliability rganoleptic Characteristics C mments 
L-  ✔ . r l t, ll i   i . rl . ft t . 
Although somewhat flexible, it 
breaks if folded i  half. 
L-  ✔✔ . r l t, ll i   i . rl . ft t .  
L-   
omoge ous. Transl cent, yellowish 
and shiny. Odourless. Sticky touch. 
The film can barely e handled 
due to its stickine s. 
ChT-a ✔✔ Ho ogen ous. Translucent, y llowish and shiny. Odourless. S ft touch.  
ChT-b ✔✔✔ Homoge eous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChT-c ✖ Heterogeneous. Opaque, yellowis  and mat . O ourless. Rough touch. 
Completely rigid, it breaks when 
ev n slight force is applied.
ChC-a ✔✔ Ho o en ous. Translucent, yellowish and sh ny. O ou less. Soft touch.  
ChC-b ✔✔✔ Homogeneous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChC-c ✖ Heterogeneous. Opaque, yellowish and m tt. O ourless. Rough touch. 
Completely rigid, it breaks when 
even s ight f ce is a p ied. 
✖: Un c pt bl ; ✔: Acc pt ble; ✔✔: Good; ✔✔✔: Exc len . 
T e m c nic l pr perties of the yst m t b  take  i to acc n  when dev lopi g film  for 
v ginal dminist ati , s the can determine c m or  and cc ptabili y fo  t e patient and m y v  
b r ated o t p f rm nc  of th  fi m once administ d. In the c se of hL-c, the format on of
polylac i a id s so pr ounced that the f lm is sticky and be ome  impossibl to h ndle. ChT-c n  C C-
 f lms were also obse v d to b igid and irr gular, which ca  e at r buted o h xcess of acid during
the r cti n, a cor obo ated by FTIR st dies (Se tion 2.2.1). The exc ss of tartaric c d or cit ic acid stiffe s
e film, a  hey r  lid substanc s. The e films ere therefore discar d fr m furt er studies. 
The co arison of the other f ms in term of the acid used for their preparation v aled that 
the film  with chitosan lac ate had the lowe deformation capacity, while those containing chitosan 
tartrate or chitosan citrate had a higher capacity. This may be related to the ability of tartaric acid and 
citric acid to act as cro slink rs, possibly facilitating the mobility of the chitosan chains [52]. In all 
cases the films prepared with the diluted acids at 0.5 M (CaL-b, ChT-b, and ChC-b) were more flexible 
than those obtained with the diluted acids at 0.25 M (ChL-a, ChT-a, and ChC-a). 
2.2.3. Drug Release Asse sment 
Chitosan derivative films prepared with the previously determined optimal concentration of 
diluted acids (ChL-b, ChT-b, ChC-b) were loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
ChC-TFV). The drug release profiles from these chitosan derivative-based films are shown in Figure 6. 
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Table 1. Characteristics observed by visual evaluati n of films based on chitosan derivatives. 
Batch Pliability rganoleptic Ch ra teristics C ments 
L-  ✔ . r l t, ll i   i . rl . ft t . 
Although somewhat flexible, it 
breaks if folded in half. 
L-  ✔ . r l t, ll i   i . rl . ft t .  
L-   
omoge eo s. Transl cent, yellowish 
nd shiny. Odourless. Sticky touch. 
The film can barely e handl d 
due to it  sti kine s. 
ChT-a ✔ H mog neous. Transl cent, yellowish and shiny. Odourless. Soft touch.  
ChT-b ✔ Homoge eo s. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChT-c ✖ H terogeneo s. Opaque, yellowish and ma . Odourless. Rough touch. 
Compl tely r gid, it breaks when 
ev n ligh  forc  is appli d.
ChC-a ✔ Homog neous. Translucent, yellowish and shiny. Odourless. Soft touc .  
ChC-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChC-c ✖ H terogeneous. Opaque, yellowish and m tt. O ou less. R ugh touch. 
Compl tely r gid, it breaks when 
ven sligh  fo ce is applied. 
✖: Una ceptabl ; ✔: A ept ble; ✔: G od; ✔: Exc llent. 
The m ch nical properties of the syst m ust be tak  into co nt when d v loping films for 
v ginal ad inist ti n, s the can d termine com ort an ac pta li y for t e p tie t and may ev  
b re ated o t perf rm nc  of fi m onc ad inis d. In the c s  of ChL-c, the forma on of
polylacti a id i  so p nounced that the f lm i  ticky and be ome  imp ssibl to h ndle. ChT-c n  C C-
 ere als obse v d o b rigid and irr gular, which n e attribut d  h xcess of aci  during
th  r cti n, a corroborated by FTIR studies (Section 2.1). Th excess f tartar c ac d or citric acid st ffe s
e film, as hey re s lid substanc s. The e films wer therefore discar d fr m furt er studies. 
The co arison of t e other f ms in terms of the acid used for their preparation rev aled that 
the film  with chitosan lac ate ha the lowes deformation capacity, while those containing chitosan 
ta trate or chitosan citrate had a higher capacity. This may be related to the ab lity of tartaric acid and 
citric acid to ct as cro slink rs, possibly fac litating the mob lity of the chitosan chains [52]. In all 
cases the films prepared with the diluted acids at 0.5 M (CaL-b, ChT-b, and ChC-b) were more flexible 
than those obtained with the diluted acids at 0.25 M (ChL-a, ChT-a, and ChC-a). 
.2.3. Drug R lease A sessment 
Chitosan derivative films prepared with the previously d termined optimal concentration of 
diluted acids (ChL-b, ChT-b, ChC-b) were loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
ChC-TFV). The drug r lease profiles from these chitosan derivative-based films are shown in Figure 6. 
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Table 1. Characteristics observed by vis al evalua ion f films based on chitosan derivatives. 
Batch Pliability Or a oleptic Characteristics Comments 
ChL-a ✔ Homogene s. Transl cent, yellowish and shiny. Odourless. Soft touch. 
Although somewhat flexible, it 
breaks if folded in half. 
ChL-b ✔✔ Homogene s. Transl cent, yellowish and shiny. Odourless. Soft touch.  
ChL-c ✖ Homogeneous. Translucent, yellowish and shiny. Odourless. Sticky touch. 
The film can barely be handled 
due to its stickiness. 
ChT-a ✔✔ Homogen ou . Tra slucent, y llowish and shiny. Odourless. S ft touch.  
ChT-b ✔✔✔ Homogeneous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChT-c ✖ Heterogeneous. Opaque, yellowish and mat . O ourless. Rou h touch. 
Completely rigid, it breaks when 
even sligh  forc  is appli d. 
ChC-a ✔✔ Homogeneous. Tra slucent, yellowish and shiny. Odourless. Soft touch.  
ChC-b ✔✔✔ Homogeneous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChC-c ✖ Het rogeneous. Opaque, yellowish and m tt. Odo rl ss. Rough touch. 
Completely rigid, it breaks when 
ven sligh  force is app ied  
✖: Unaccept ble; ✔: Acc pt ble; ✔✔: Good; ✔✔✔: Exc llen . 
T e m c nical propertie  of t e yst m u t b  t ken into accou t when d velopi g film  f r 
v gin l adm nistr ti , as t ey can determine o or and c ptabili y for the pa ient and m y even
be e ated to  p rf rm nc  of the fi m n a mi ist r d. In he cas  of C L-c, t e f rmat o  f
polylac i  a id s s  n unced that the film i stick  and becom s imp ssibl  to han le. ChT- nd ChC-
 f lms were also obse ve  o  igid and irr gular, hic  can e at ributed to e excess of aci  uring
the r action, a co ob at by FTIR st dies (Section 2.2.1). The excess f tart ric acid o  cit ic acid stiff ns
e film, a th y r  olid substa c s. The e films we e herefore disc r e from further studies. 
The c mpari o of h  other films in terms of t e acid us d for heir preparati n revealed th t 
the films with chi osan lactate had the lowest deforma ion capacity, while t ose co taini g chitosan 
tartrate or chito an citrate had a igher cap ity. This may be related to the ability of tartaric acid and 
citric acid t ac  as crosslinkers, possibly facilitating the mobility of the c itos n chains [52]. In all 
cases the films prepared with the diluted acids at 0.5 M (CaL-b, ChT-b, and ChC-b) were more flexible 
than those obtain d with the diluted acids at 0.25 M (ChL-a, ChT-a, and ChC-a). 
2.2.3. Drug Release Assessment 
hitosan d rivative films prepa ed with the previously determin  optimal c nce tration of
diluted acids (ChL-b, Ch -b, ChC-b) were loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
ChC-TFV). The drug release profiles from these chitosan derivative-based films are shown in Figure 6. 
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Table 1. Characteristics ob erved by visual evaluati n of films based on chitosan derivatives. 
Batch Pliability Organoleptic Ch racteristics Co ments 
ChL a ✔ Homogeneous. Translucent, yellowish and s iny. Odourless. Soft touch. 
Although somewhat flexible, it 
br aks if folded in half. 
ChL-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChL-c ✖ Homogeneous. Translucent, yellowish and shiny. Odourl ss. Sticky touch. 
The film can barely be handled 
due to it  stickiness. 
ChT-a ✔ H mog n ous. Transl cent, y llowish and sh ny. Odourl ss. S ft touch.  
ChT-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChT-c ✖ H terogeneous. Opaque, yellowish and mat . O ourl ss. Rough touch. 
Compl tely r gid, it breaks when 
even sligh  fo c  is appli d. 
ChC-a ✔ Homogen ous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChC-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChC-c ✖ H ter geneous. Opaque, yellowish an  m tt. Odo rless. Rough touch. 
Compl tely r gid, it breaks when 
ven sligh  force is app ed. 
✖: Unacceptable; ✔: Ac ept ble; ✔: G od; ✔: Exc llen . 
T e mec nical properti of t  syst m u t b  tak n into count when developing film for 
v gin l ad nistrati , as t ey c n d ter ne com or n accep ab li y for the p tie t and m y even
be e ated to  p f rm nc  of film on ad inist red. In he cas  f C L- , t e forma o  of
polylac ic a id  so onounced that th  film i  s cky and becom s imp ssibl  to han l . ChT-  an  ChC-
 f lms w re als obse ve  o e igi n  irr gular, hic  can  at ributed to h  excess of aci  during
th  r action, a co ob a ed by FTIR st dies (Secti n 2.1). Th excess f tartaric acid or cit ic acid st ffens
e fil , a  t ey r  olid subs nc s. The e films were herefore discar d from fur her studies. 
The comparison of e other films in terms of the acid us d for heir preparation revealed that 
the films with chitosan lactate had the owest deforma ion capacity, while t e containing chitosan 
ta trate or chitosan citrate had a higher c pacity. This may be related to the ab lity of tartaric acid and 
citric acid t  ct as cro slinkers, possibly fac litating t e mob lity of the c itosan chains [52]. In all 
cases the films prepare  with the diluted acids at 0.5 M (CaL-b, ChT-b, and ChC-b) were more flexible 
than those obtain d with th  diluted acids at 0.25 M (ChL-a, ChT-a, and ChC-a). 
.2.3. Drug R lease Assessment 
Chitosan erivative films prepa ed with the previously d termined optimal c centration of 
diluted acids (ChL-b, ChT-b, ChC-b) were loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
ChC-TFV). The drug r lease profiles from these chitosan derivative-based films are shown in Figure 6. 
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Table 1. Characteri tics ob rved by vi ual ev luati n of films based on chitosan derivatives. 
Batch Pliability Organoleptic Ch racteri tics Co ments 
hL-a ✔ Homogeneous. Translucent, yellowish and shiny. Od url ss. S ft touch. 
Although somewhat fl xible, it 
break if folded in half. 
ChL-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. S ft touch.  
ChL-c ✖ Homogeneous. Translucent, yellowish and shiny. Odourless. Sticky touch. 
The film can barely be handled 
due to it  stickiness. 
ChT-a ✔ H mog neous. Transl cent, yellowish and shiny. Odourles . S f  touch.  
ChT-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. S ft touch.  
ChT-c ✖ H terogeneous. Opaqu , yellowish and mat . Odourl ss. Ro gh tou .
Comp tely r gid, it breaks when 
even sligh  force is applied. 
ChC-a ✔ Homogeneous. Translucent, yellowish d shiny. Odourless. S ft touch.  
ChC-b ✔ Homogeneous. Translucent, yellowish and shiny. Odourless. S ft touch.  
ChC-c ✖ H terogeneous. Opaqu , yellowish an  m t. Odourles . Roug  touch
Comp tely r gid, it breaks when 
ven sligh force is appl ed. 
✖: Unacceptable;✔: Ac p ble; ✔: G od; ✔ ✔: Excelle t. 
The m nical properties of t  yst  ust be tak  in o coun wh n dev loping film or 
vaginal ad inis ra i , as y c n d ter ne com ort n accep ab l y for the p tie t and may even
b  re ated to t  pe f r nc of film onc  ad nistered. In he cas  f ChL- , the forma o of
polylactic id i  so p onounced ha  th  film i  s cky and come  imp ssibl to handl . ChT-  an  hC-
s w re ls ob ved to be rigi n  irregular, w i  can ttributed t  h  xces of aci  during
th  reaction, a c r ob ra d by FTIR stud es (Secti n 2.1). Th xcess of tartaric cid r cit ic ci  s ffens
e fil , as t ey are olid subs nc s. Th e films were therefore discar d from fur her studie . 
The comparis n of t e ot er films in terms of the acid used for t ei  reparation rev aled hat 
the films wit chito an l ctate had the owest deformation capacity, while th e ontaining chitosan 
a rate or chitosan ci rate h d a igher c paci y  This may e related to the ab lity of tari  acid and 
citri  acid to ct as crosslinkers, possibly fac litating t e mob lity of the chitosan chains [52]. In all 
cases the films repared wit  the diluted acids at 0.5 M (CaL-b, ChT-b, and hC-b) were mor  flexible 
than those obtain d wit  th  diluted acids at 0.25 M (ChL-a, ChT-a, and hC-a). 
.2.3. Drug R l ase A essment 
Chitosan erivative films repared wi  the previously d termined optimal co centration of 
diluted acids (ChL-b, ChT-b, hC-b) were loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
hC-TFV). The drug l ase profiles from these chitosan derivative-based films are shown in Figure 6. 
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Table 1. Characteristics observed by visual evaluation of films based on chitosan derivatives. 
Batch Pliability Organ leptic Characteristics Comments 
ChL-a  
Homoge eous. Tran lucent, yellowish 
and shiny. Odourle . Soft touch. 
Although somewhat flexible, it 
breaks if folded in half. 
ChL-b ✔✔ Homoge eous. Tran lucent, yellowish and shiny. Odourle . Soft touch. 
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ChC-c ✖ Heterogeneous. Opaque, yellowish an  matt. Odourless. Rough touch. 
Completely rigid, it breaks when 
even slig t force is applied. 
: U acceptable; ✔: Accept ble; ✔✔: Go d; ✔✔✔: Excellent. 
T e mecha ical properties of t e syst m us be taken into account when developing films for 
vaginal administration, as they can determine com ort and acceptabili y for the patient and may even
be re ated to the performanc  of the fi m once administered. In the case of ChL-c, the format on of
polylactic a id is so pronounced that the film is sticky and becomes impossibl to handle. ChT-c and ChC-
 films were also obse ved to be rigid and irregular, which can e attributed to he excess of acid during
the reaction, a corroborated by FTIR studies (Section 2.2.1). The excess of tartaric acid or citric acid stiffens
e film, as they are solid substanc s. The e films were therefore discar ed from further studies. 
The comparison of the other films in terms of the acid used for their preparation revealed that 
the films with chitosan lactate had the lowest deformation capacity, while those containing chitosan 
tartrate or chitosan citrate had a higher capacity. This may be related to the ability of tartaric acid and 
citric acid to act as crosslinkers, possibly facilitating the mobility of the chitosan chains [52]. In all 
cases the films prepared with the diluted acids at 0.5 M (CaL-b, ChT-b, and ChC-b) were more flexible 
than those obtained with the diluted acids at 0.25 M (ChL-a, ChT-a, and ChC-a). 
2.2.3. Drug Release Assessment 
Chit san d iv tive films prepar  with the previously d t rmi  optimal concent atio  of 
diluted aci s (ChL-b, C T-b, ChC-b) were lo ded with 30 g of FV (batches hL-TFV, ChT-TFV d 
ChC-TFV). The drug r lease profiles from these chitosan derivative-base  films are shown in Figure 6. 
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Table 1. Characteristics bs rved by v ual evaluation of films bas d on chitosan derivatives. 
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ChL-a ✔ Hom geneous. Translucent, yellowish and shiny. Odour e s. Soft touch. 
Although somewhat flexible, it 
breaks if folded in half. 
ChL-b ✔✔ H m geneous. Translucent, yellowish and shiny. Odour ess. Soft touch.  
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due to its stickin ss. 
ChT-a ✔✔ Hom ge eo s. Translucent, yellowish and shiny. Odourle s. Soft touch.  
ChT-b ✔✔✔ Hom geneous. Translucent, yellowi h and shiny. Odourless. Soft touch.  
ChT-c ✖ Heterogeneous. Opaque, yellowish and matt. Od urless. Rough touch. 
Completely rigid, it breaks when 
even slight force is applied. 
ChC-a ✔✔ Ho ogeneous. Tran lucent, yellowish and shiny. Od urless. Soft touch.  
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ChC-c ✖ Heterogeneous. Opaque, yellowish and matt. Odourless. Rough touch. 
Completely rigid, it breaks when 
even slight force is applied. 
✖: Unacceptable; ✔: A ceptable; ✔✔: Good; ✔✔✔: Excellent. 
The mechanic l properties f the system must be taken into account when developing films for 
vaginal administration, as they can determine comfort and acceptability for t e patient and may even 
be related to the performance of t e film once administered. In the case of ChL-c, the formation of 
polylactic acid is so pronounced that the film is sticky and becomes impossible to handle. ChT-c and ChC-
c films were also observed to be rigid and irregular, which can be attributed to the excess of acid during 
the reaction, as corroborated by FTIR studies (Section 2.2.1). The excess of tartaric acid or citric acid stiffens 
the film, as they are solid substances. Thes  f lm  wer  therefore discarded from further studies. 
The comparison of the other films n terms of the acid us d for their preparation revealed that 
the films with chito an lactate had the lowest deformation capacity, while those containing chitosan 
tartrate or c itosan citrate had a higher capacity. This may e r lated to the ability of t rtaric acid and 
citric acid to ct as cro slinkers, poss bly f cilitating the mobility of the chitosan chains [52]. In all 
cases the films prepared with the diluted acids at 0.5 M (CaL-b, Ch -b, and ChC-b) were more flexible 
than those obtained with the iluted acids at 0.25 M (ChL-a, ChT-a, and ChC-a). 
2.2.3. D  R l ase Ass ssment
Chitosan derivative films prepared with the previously determined optimal concentration of 
diluted acid  (ChL-b, ChT-b, ChC-b) were loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
ChC-TFV). The drug release profiles from these chitosan derivative-based films are shown in Figure 6. 
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Tabl  1. Char ct ristics bserved by visual evaluation of fi ms based on chitosan derivatives. 
Batch Pl ability Organoleptic Characteristics Comments 
ChL-a ✔ H mogene us. Tr slucent, yellowish and shiny. Odourless. Soft touch. 
Although somewhat flexible, it 
breaks if folded in half. 
ChL-b ✔✔ Homogeneous. Translucent, yellowish nd shiny. Odour ess. S t touch.  
ChL-c ✖ Homogeneous. Tr ns ucent, y llowish and shiny. Odourless. Sticky touch. 
The film can barely be handled 
due to its stickiness. 
C T-a ✔✔ Homogene us. Tr slucent, yellowish and shiny. Odourless. Soft touch.  
ChT-b ✔✔✔ Homogeneous. Translucent, yellowish and shiny. O ourles . Soft t uch.  
ChT-c ✖ Heterog neous. Opaque, yellowish a d matt. Odourless. Rough touc . 
Complet ly rigid, it breaks when 
even slight force is applied. 
ChC-a ✔✔ Homogeneous. Translucent, yellowish and shiny. Odou less. Soft touch.  
ChC-b ✔✔✔ Ho geneous. Tr ns ucent, yellowis  nd shiny. Odourless. Soft tou h.  
ChC-c ✖ Heterogeneous. Opaque, yellowish and matt. Odourless. Rough touch. 
Completely rigid, it breaks when 
even slight force is applied. 
✖: Unacceptable; ✔: Acceptable; ✔✔: Good; ✔✔✔: Excellent. 
The mechanical properties of the syste  must be taken into account when developing films for 
vaginal administration, as they can determine comfort and acceptability for the patient and may even 
be related to the performance of the film o ce ad inistered. In the case of ChL-c, the formation of 
polylactic acid is so pronounced that the film is sticky and becomes impossible to handle. ChT-c and ChC-
c films were also observed to be rigid and irregular, which can be attributed to the excess of acid during 
the reaction, as corroborated by FTIR studies (Section 2.2.1). The excess of tartaric acid or citric acid stiffens 
the film, as they are solid substances. These films were therefore discarded from further studies. 
The comparison of the ot er films in terms of the aci  used for their preparati n revealed that 
the films with c itosan lactate ha  the lowest deformation capacity, while those co taining chitosan 
tartrate or chitosan citrate had a higher capacity. This may be related to the ability of tartaric acid and 
citric acid to act as crosslinkers, possibly facilitating the mobility of the chitosan chains [52]. In all 
cases the films prepared with the diluted acids at 0.5 M (CaL-b, ChT-b, and ChC-b) were more flexible 
than those obtained with the diluted acids at 0.25 M (ChL-a, ChT-a, and ChC-a). 
2.2.3. Drug Release Assessment 
Chitosan derivative films prepared with t e previously determined optimal concentration of 
diluted acids (ChL-b, ChT-b, ChC-b) were loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
ChC-TFV). The drug release profiles from these chitosan derivative-based films are shown in Figure 6. 
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Ta l  1. Characteristics observed y v su l evaluation of films base  on ch tosan derivatives. 
Batch Pliability Org noleptic Characteristics Comments 
ChL-a ✔ Homogeneous. Translucent, yellowisand hiny. Odourless. Soft touch. 
Although somewhat flexible, it 
breaks if folded in half. 
ChL-b ✔✔ Homogeneous. T anslucent, yellowish a d iny. Odourl ss. Soft touch.  
ChL-c ✖ Homogeneous. Tra slucent, yellowi h and hiny. Od rless. Sticky touch. 
The film can barely be handled 
due to its stickiness. 
ChT-a ✔✔ Homogeneous. Translucent, yellowish and hiny. Odourless. Soft touch.  
ChT-b ✔✔✔ Homogeneous. Translucent, yellowis  and hiny. Odourl ss. S ft to c .  
ChT-c ✖ Heterog neous. Opaque, yellowish and matt. Odourless. Rough touch. 
Compl tely rigid, it breaks when 
ven slight force is applied. 
ChC-a ✔✔ Homogeneous. Translucent, yellowish and hiny. Odourless. Soft touch.  
ChC-b ✔✔✔ Homog e us. Translucent, yellowish and hiny. Odourl ss. Soft touch.  
ChC-c ✖ Heterog ne us Opaque, yellowish and matt. Odourless. Rough touch. 
Compl tely rigid, it breaks when 
ven slight force is applied. 
✖: Unacceptable; ✔: A cep ble; : Good;✔✔✔: Excellent. 
The mechanical properties of the system mus  be take  into account when developing films for 
vagin l administratio , as they ca  determi e comfort and acceptability for the p tient and may even 
be related to the performance of the film onc  administered. In t e case of ChL-c, the formation of 
polylactic acid is so pronounced that the film is sticky and becomes impossible to h le. ChT-c and ChC-
c films wer  also observed to be rigid and irregular, which can be attribut d t  the excess of acid during 
the reacti n, as corrobora e  by FTIR studies (Section 2.2.1). The ex ess of tarta i  i  or citric acid stiffens 
the film, as they are solid sub tance . These films were therefore discarded from further studies. 
The comparison of the other films in terms f the acid used for their prep ration revealed that 
t e f lms ith chitosan lactate had the lowest deformation capacity, while those contai ing chitosan 
tartr te or chitosan citrat  had  higher capacity. This may be related t  the ab lity of tartaric acid and 
citric acid to act as cr sslinkers, possibly facilitat ng the mobil y of the chitosan chains [52]. In all 
cases the films prepared with the diluted acids at 0.5 M (CaL-b, ChT-b, and ChC-b) were more flexible 
th n those ob ained with the diluted acids at 0.25 M (ChL-a, ChT- , and ChC-a). 
2.2.3. Drug Release Assessment 
Chitosan derivative films prepared w th the pr viously determined optimal concentration of 
diluted acids ChL-b, ChT-b, ChC-b) ere loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
ChC-TFV). Th  drug release profiles from these chi osan d rivative-based films are shown in Figure 6. 
0 1 2 3 4 5 6
0
20
40
60
80
100
Te
no
fov
ir r
ele
as
ed
 (%
)
Time (h)
 ChL-TFV
 ChT-TFV
 ChC-TFV
 
Mar. Drugs 2020, 18, x FOR P E  REVIEW 7 of 21 
 
Tabl  1. Ch racteristics obser ed by visu l evalu tion of films based on chitosan derivatives. 
Batch Pliability Organoleptic Ch racteristics Co ments 
ChL-a ✔ Homog eous. Translucent, yellowish and shiny. Odourless. Soft touch. 
Al hough somewhat flexible, it 
breaks if folded in half. 
ChL-b ✔ Homog eous. T ansluc t, yellowish and s iny. Odourl ss. Soft touch.  
ChL-c ✖ Homog eous. Translucent, yell wish and shiny. Odourless. Sticky touch. 
The film can barely be handled 
due to it  stickiness. 
ChT-a ✔ Homog eous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChT-b ✔ Homog ous. Translucent, y llowish d shiny. Odour ss. S ft touch.  
ChT-c ✖ H terogen us. Opaque, y llowish a d matt. Odourless. Rough touch. 
Compl tely r gid, it breaks when 
even slight force is applied. 
C C-a ✔ Homog eous. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChC-b ✔ Homog e us. ranslucent, yellowish and shiny. Odou l ss. Soft touch.  
ChC-c ✖ H terogene us. Opaque, yellowish and matt. Odourless. Rough touch. 
Compl tely r gid, it breaks when 
even slight force is applied. 
✖: Una : Acceptable; ✔✔: G od; ✔: Excellent. 
The mechanical proper ies of the system must be taken into account when developing films for 
vaginal administration, as they can d termine o fort and acceptab lity for the patient and may even 
be related to the performance of the f lm once administer d. In the cas  of ChL-c, the formation of 
polylactic acid i  so pronounced that the film i  sticky and beco es impossible to handle. hT-c and ChC-
c film  were als  observed to b  rigid and irregular, which can be attributed to th excess of aci  during 
the reaction, as corroborated by FTIR studies (Section 2.1). Th  excess f tartaric acid or citric acid stiffens 
the film, as they are solid substances. These films were therefo e discard d from further studies. 
The comparison of the ther films in terms of the acid used f r thei  pr para ion revealed that 
the films with chitosan lactat  had the lowest deformation capacity, while those c ntaining chitosan 
ta trate or chitos n citrate had a higher capacity. This may b related to the ab lity of tartaric acid and 
ci ric acid to act as cro slinkers, possibly fac litat ng the mob lity of the chitosan chains [52]. In all 
cas s th  films prepared with the diluted acids at 0.5 M (CaL-b, ChT-b, and ChC-b) wer  more flexible 
than those obtained with the diluted acids at 0.25 M (ChL-a, ChT-a, and ChC-a). 
.2.3. Drug R l ase Assessment 
Ch tosan derivative films prepared with the previously d termined optimal c ncentration of 
diluted acids (ChL-b, ChT-b, Ch -b) were loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
ChC-TFV). The drug r lease profiles from th se chitosan derivative-based films are shown in Figure 6. 
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T ble 1. Characteristics o se ved by visual evaluation of films bas d o chitosan derivatives. 
Batch Pliability Organoleptic Characteristics Comments 
C L-a ✔ Hom g neo s. Translucent, yellowis  and hiny. Odourless. So t touch. 
Although somewhat flexible, it 
breaks if fo ded in half. 
C L-b ✔✔ Hom geneo s. Translucent, yellowish and shi y. Odourless. Soft touch.  
C L-c ✖ Hom geneo s. Translucent, yellowish and shiny. Odourless. Sticky touch. 
The fi m can b rely be handled 
due to it  stickiness. 
ChT-a ✔✔ Hom g neo s. Translucent, yellowish and hiny. Odourless. Soft touch.  
ChT-b ✔✔✔ Hom geneo s. Tr nsluce t, yellowish a d shi y. Odo less. S ft t uch.  
ChT-c ✖ Heterogeneous. Op qu , yellow sh and matt. Od rless. Rough touch. 
Completely rigid, it breaks when 
even sl ght force is applied. 
ChC-a ✔✔ Hom geneo s. Translucent, yellowish and shiny. Odourless. Soft touch.  
ChC-b ✔✔✔ H geneo s. ransluce t, yellowish nd shi y. Odourles . Soft touch.  
ChC-c ✖ Heterogeneou . Opaque, yellow sh and matt. Od rless. Rough touch. 
Completely rigid, it breaks when 
even sl ght force is applied. 
✖: Unacceptable; ✔: Acceptable; ✔ : Good; ✔✔✔: Excellent. 
Th  mec anical propertie  of the system m st be aken i  account when developing films for 
vaginal d inis ratio , as they c  ter ine com t and ccept bility for the patient and may even 
be relat d to the perf rmance of the film o ce dminis ered. In the case of ChL-c, the f rmation of 
p lylactic acid is so pronounced that the film is sticky and bec mes imp ssib  to andle. ChT-c and ChC-
c films we  also observed to be rigid a d irregular, whic  can be attribut  to the ex ess of acid during 
the rea ti n, as corro orated by FTIR studies (Section 2.2.1). The excess of tartaric a d or citr c acid stiffens 
the film, s they ar  sol d substanc s. Thes  films w  therefo  di carded from furth r studies. 
The c mparis n of the ot r fil s in terms f the acid used for th ir preparation revealed that 
the films with chitosan l ctat  h d he l west deform t on apaci y, while hose conta ning chitosan 
t rtra e or chitosa  citr e ad  higher capacity. T is may be related to he bili y of tartaric acid and 
citric id to act as cro slinkers, possibly facilitating the mobility of the ito an chains [52]. In all 
case  t  films prep red with he diluted acids at 0.5 M ( aL-b, ChT-b, and ChC-b) w re mor flexible 
than thos ob aine  with he diluted acids at 0.25 M ( hL- , ChT-a, nd ChC-a). 
2.2.3. Drug Release Assessment 
Chitosan d rivat ve films prepared with the previously d termined ptimal concentration of 
diluted acids (ChL-b, ChT- , C-b) w re loaded with 30 mg of TFV (batches ChL- FV, ChT-TFV and 
ChC-TFV). Th  drug r l ase profiles f om these chitos n derivative-ba ed films are shown in Figure 6. 
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T bl 1. haracteristics ob e ve  by visual evaluation of films ba ed on chitosan derivatives. 
Batch Pl ability Organol ptic Ch racteristics Co ments 
C L-a ✔ Homogeneous. Translucent, yellowish a d shiny. Od rless. Soft touch.
Although somewhat flexible, it 
breaks if folded in half. 
C L-b ✔ Homogeneous. Translucent, yellowish d shi y. Od rless. Soft touch.  
ChL-c ✖ Homogeneous. Transluce t, yellow sh and shiny. Odourless Sticky touch
Th  fi m can barely be handled 
du  to it  stickiness. 
ChT-a ✔ Homogeneous. Translucent, yellowish a d shiny. Od rless. Soft touch.  
ChT-b ✔ Homoge eous. Transluce t, yellowish a d shiny. Od rless. S ft touch.  
ChT-c ✖ H terogeneous. Opaque, ellowish and matt. Odourless. Rough t uch. 
Compl t ly r gid, it breaks when 
even slight force is applied. 
ChC-a ✔ Homogeneous. Translucent, yellowish and hiny. Od rless. Soft touch.  
ChC-b ✔ Homogeneous. Translucent, yellowish nd shi y. Od rles . Soft touch.  
ChC-c ✖ H terogeneous. Opaque, ellowish and matt. Odourless. Rough touch. 
Compl t ly r gid, it breaks when 
even slight force is applied. 
✖: Unacc ptable; ✔: Acceptable : G od; ✔: Excellent. 
The echanical prop rti s of the yst m must be taken i o account whe  developing films for 
vag nal dministration, as t ey ca d t rmine comfort nd accep ab lity for the patient and may even 
be related to the perf rmance of the fil  o ce adminis red. In the case of ChL-c, the f rmation of 
polylactic cid i  so pronounced that he film i  sticky and bec mes impossib  to andle. T c and ChC-
c films wer  als o s rve  to be igid nd irreg l r, which can be at ribut d to th  excess of aci  during 
the reacti n, s corroborated by FTIR studies (Sec ion 2.1). Th  excess of ta taric a id or citric acid stiffens 
the film, as they are o id substances. Th s  films we  therefore discarded f om further studies. 
The com ar s n of the other fil  in te ms of th  acid used for the r p paration revealed that 
the films wi  hi osan lactate had he l west deform on capac y, while hose con aining chitosan 
ta r te or chitos n citrate ad  high capaci y. This ma be r l ted to the ab lity of tartaric acid and 
citri  acid t  act as crosslinkers, possib y fac litating the mob lity of the ito an chains [52]. In all 
ca e  th  films prepare  with the iluted acids t 0.5 M (CaL-b, ChT-b, and ChC-b) w re more flexible 
an those ob ine  with the iluted acids t 0.25 M (ChL- , ChT-a, nd ChC-a). 
.2.3. Drug R lease Assessment 
Chitosan deriva ive films prepar  with the pr viously d ter ined ptim l concentration of 
diluted acids (ChL-b, T b, ChC-b) were loaded with 30 mg of TFV (batches ChL-TFV, ChT-TFV and 
C C-TFV). Th  drug release profiles from these chitosan d rivat ve-b sed films are shown in Figure 6. 
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T bl 1. har te i tics b rve  by visual ev luati n of films ba e on ch tosan derivatives. 
Ba ch Pliability Org nol ptic Ch racteri tic  Co ments 
C L-a ✔ H mogeneous. Tran lucent, yellowisand shiny. Od rless. S ft touch. 
Although somewhat flexible, it 
breaks if folded in half. 
C L-b ✔ H mogeneous. Tran lucent, yellowish and shiny. Od rl ss. S ft touch.  
ChL-c ✖ H mog e us. Translucent, yellow sh and shiny. Od rless Sticky touch. 
Th film can barely be handled 
du  to it  stickiness. 
ChT-a ✔ H mogeneous. Tran lucent, yellowish and shiny. Od rless. S ft touch.  
ChT-b ✔ H m gen ous. Tran lucent, yellowish and shiny. Od rless. S ft touch.  
ChT-c ✖ H t rog eous. O aqu , yellowish and matt. Odourl ss. R u  tou h. 
Comp t ly r gid, it breaks when 
ven slight force is applied. 
ChC-  ✔ H mogeneous. Tran lucent, yellowish and shiny. Od rless. S ft touch.  
ChC-b ✔ H mogeneous. Tra lucent, yellowish nd shi y. O rless. S ft touch.  
hC-c ✖ H terog neo s. O aqu , yellowish and matt. Odourl ss. Rou  tou h. 
Comp t ly r gid, it breaks when 
ven slight force is applied. 
✖: Unacceptable : Accept ble : G od; ✔ ✔: Excellent. 
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structures, so hC-TFV and ChT- FV could be expected to show a greater capacity for controlle
drug release than ChL-TFV, which should release the drug at the fastest rate. While this behaviour is
indeed observed, there are insufficient differences between the formulations. This can be explained by
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the fact that they form gels with a very low consistency, as was observed in the gel characterization
studies (Section 2.1). For this reason, and to modulate the gelation rate of chitosan derivatives,
and consequently the release of TFV, it was decided to prepare LbL films using ES100.
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Figure 6. Tenofovir release from the films containing chitosan lactate (ChL-TFV), chitosan tartrate
(ChT-TFV) and chitosan citrate (ChC-TFV).
2.3. Layer-by-Layer Films
In order to improve the properties of the chitosan derivatives, LbL films were prepared using the
previously selected chitosan derivative-based films (ChL-TFV, ChT-TFV and ChC-TFV). Six different
batches were obtained by adding a layer of ES100 (plasticized with Triethylcitrate (TEC)) of 75 mg
(ChL/E-a, ChT/E-a and ChC/E-a) or 150 mg (ChL/E-b, ChT/E-b and ChC/E-b). As seen in the SEM
micrographs (Figure 7), the layers were tightly joined and LbL films were obtained.
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2.3.1. Texture Analysis
Figure 8 shows the deformability of the films, determined through texture analysis.
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The films containing chitosan lactate (ChL/E 1 and ChL/E 2) have the lowest deformability values.
Films based on chitosan tartrate (ChT/E 1 and ChT/E 2) exhibit a higher deformation capacity compared
to ChL/E films. Chitosan citrate-based films (ChC/E 1 and ChC/E 2) have the highest deformability.
According to the ANOVA processing, the differences are statistically significant (p-value = 1.85 × 10−11).
The proportion of ES100 also conditions the deformability of the systems with statistically significant
differences (p-value = 7.73 × 10−3), which can be attributed to the thickness of the ES100 layer. It is
therefore necessary to apply a slightly greater force to obtain the same deformation when this layer is
double the thickness.
These results can be explained by the fact that lactic acid is unable to crosslink chitosan chains.
Conversely, tartaric acid and citric acid act as crosslinkers for chitosan, which is why these films
(ChT/E and ChC/E) present better mechanical properties, as the mobility of the polymer chains may be
enhanced by the presence of crosslinkers [52]. Among the films evaluated, those based on chitosan
citrate (ChC/E-a and ChC/E-b) can therefore be considered to have the best mechanical properties,
followed by films based on chitosan tartrate (ChT/E-a and ChT/E-b); films prepared with chitosan
lactate (ChL/E-a and ChL/E-b) are the least appealing. However, all the films show good properties for
handling and application, since they are highly resistant and flexible.
2.3.2. Swelling Behaviour
The results of the swelling behaviour assessment in simulated vaginal fluid (SVF) are shown in
Figure 9. In the case of films based on chitosan lactate and ES100, it can be observed that the maximum
amount of water imbibed is significantly greater when the ES100 layer is thicker. ChL/E-a shows
a maximum swelling ratio (SRmax) of ≈ 200% while ChL/E-b has a SRmax of ≈ 320%. The complete
dissolution of the derivative (which leads to the constant weight of the formulation) occurs in both
cases at 168 h. These results show a certain incompatibility between the layers, since an increase in the
thickness of the ES100 layer leads to an increase in the water uptake rate and in the SRmax.
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Figure 9. Swelling profiles of the LbL films in SVF. 
The profiles of the batches based on chitosan tartrate (ChT/E-a, ChT/E-b) are practically overlapping, 
which implies that the presence of the ES100 layer does not condition the swelling process in this 
medium. Their low SRmax (less than 100%) indicate that these films swell very little. The swelling profiles 
of the films based on chitosan citrate and ES100 (ChC/E-a and ChC/E-b) also overlap, suggesting that 
the thickness of the ES100 layer does not condition the water uptake capacity, as observed in ChT/E 
films. These films also have the lowest SRmax values in SVF (less than 75%). 
These results can be explained by the fact that that the three-dimensional structure generated by 
crosslinkers in chitosan hinders water penetration [53], so although CL/E films show a higher 
Figure 9. Swelling profiles of the LbL films in SVF.
The profiles of the batches based on chitosan tartrate (ChT/E-a, ChT/E-b) are practically overlapping,
which implies that the pre nce of t e ES100 l yer does not condition the swelling process in this
medium. Their low SRmax (less than 100%) indicate that these films swell very little. The swelling
profiles of the films based on chitosan citrate and ES100 (ChC/E-a and ChC/E-b) also overlap, suggesting
that the thickness of the ES100 layer does not condition the water uptake capacity, as observed in
ChT/E films. These films also have the lowest SRmax values in SVF (less than 75%).
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These results can be explained by the fact that that the three-dimensional structure generated by
crosslinkers in chitosan hinders water penetration [53], so although CL/E films show a higher swelling
capacity, all the films could be useful for developing mucoadhesive vaginal formulations, since they
swell so little that they would be extremely comfortable for the patient.
2.3.3. Ex Vivo Mucoadhesion
Ex vivo mucoadhesion was determined through texture analysis on excised bovine vaginal mucosa
in SVF, and the data are shown in Figure 10. According to the results, ChL/E films have the lowest
values for mucosal stickiness (represented by the work required to detach them) and adhesiveness
(detachment force). This is because these films show the highest SRmax. According to previously
published results [54], the amount of water imbibed is inversely related to the mucoadhesion capacity
of a formulation, as water hinders the interaction between the polymer and the mucosa. ChT/E and
ChC/E therefore show higher values for mucosal stickiness, adhesiveness or both. The results reveal
that the amount of ES100 also conditions the mucoadhesion capacity of the ChT/E and ChC/E films,
probably because ES100 acts as a support capable of holding the chitosan derivative. Thus the greater
the amount of ES100, the greater the ability of the chitosan to bind to the mucosa. In the case of ChC/E
films, the difference between the formulations points to a synergy between the layers, and shows
that increasing the thickness of the ES100 layer substantially improves the mucoadhesion capacity of
the chitosan derivative-based layer. Finally, it should be noted that ChC/E-b shows a slightly higher
mucoadhesion capacity than ChT/E-b. The ChC/E-b film thus has a high mucoadhesion capacity,
superior to the formulations previously developed, which remained mucoadhered for 120 h [18].
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2.3.4. Drug Release 
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Figure 10. Ex vivo mucosal adhesiveness and stickiness obtained for the LbL films, determined in
excised vaginal bovine mucosa and SVF. Mucosal adhesiveness is represented by the white bars (values
on the left axis), and mucosal stickiness is by the black bars (values on the right axis).
2.3.4. Drug Release
Drug release data from the systems in SVF and SVF/SSF are shown in Figure 11. All the systems
exhibited an ability to release the drug in a controlled manner in SVF (in all cases the release lasts more
than 48 h), while a burst release is observed in SVF/SSF for all the systems (the complete amount of
drug is released in less than 6 h).
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According to Figure 11A, fil s based on chitosan lactate (ChL/E-a and ChL/E-b) sho a sustained
release of TFV of up to 48 h in SVF and 6h in SVF/SSF. In films based on chitosan tartrate (ChT/E-a and
ChT/E-b), whose release profiles are shown in Figure 11B, TFV release in SVF extends up to 96 h, and 4 h
in SVF/SSF. In films containing chitosan citrate (ChC/E-a and ChC/E-b), the release of TFV in SVF is
maintained for 120 h, while in SVF/SSF the totality of the drug is released in 4 h, as seen in Figure 11C.
These findings are closely related to the swelling behaviour of LbL films, where the swelling of ChL/E-a
and ChL/E-b is greater in SVF; as they have the highest penetration of water in the system, the TFV
molecules are more easily accessed by the water in the medium, accelerating the drug dissolution.
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The SRmax is slightly higher in ChT/E films than in ChC/E films, which explains why ChC/E films
show the most extended release and also confirms that crosslinking chitosan improves the capacity to
control drug release, as chitosan tartrate and chitosan citrate-based films show better controlled release
than chitosan lactate-based films. A comparison of tartaric acid and citric acid suggests that citric acid
is the best crosslinker and has the most persistent TFV release. However, this confirms the need for
an upper layer based on ES100 to enhance the properties of the crosslinked chitosan.
According to the f2 statistic (Table 2), no significant differences are observed in the release profiles
for ChL/E and ChT/E in SVF when comparing the release from films in SVF based on the amount of
ES100 in the upper layer. As seen in the swelling test results, this implies that the entry of water into
the formulation is modulated by the presence of ES100 regardless of the thickness of the layer, which
is key to the capacity to modulate drug release. However, ChC/E films show differences in release
depending on the thickness of the ES100 layer, once again indicating a synergy between the chitosan
citrate and ES100, as was observed in the mucoadhesion studies (Section 2.3.3). In SVF/SSF the entry of
water is so accelerated that the difference in release based on the thickness of this layer is negligible,
and they all release the drug in similar times. It is verified by statistical f2 that the release profiles of
LbL films are strongly conditioned by pH, due to the fact that ES100 is a pH-sensitive polymer that
becomes soluble in aqueous media at a pH of over 7 [55]. In consequence, the dissolution of the ES100
in the medium leaves the chitosan solely responsible for the release of Tenofovir, and this polymer will
release the drug in less than 8 h, as already verified in the release profiles of chitosan derivative-based
films (Section 2.2.3).
Table 2. Results of f2 processing for drug release from LbL films.
ChL/E-a SVF ChL/E-b SVF/SSF
ChL/E-a SVF/SSF 19.68 59.96
ChL/E-b SVF 73.63 21.21
ChT/E-a SVF ChT/E-b SVF/SSF
ChT/E-a SVF/SSF 14.34 34.43
ChT/E-b SVF 64.99 9.72
ChC/E-a SVF ChC/E-b SVF/SSF
ChC/E-a SVF/SSF 13.00 50.80
ChC/E-b SVF 43.01 11.71
The interest of this finding lies in the ability of the ChC/E-b film to offer women effective protection
for a maximum of 120 h, generating a much higher concentration of TFV in the vaginal environment
after ejaculation during sexual intercourse. This points to a high efficiency in the prevention of sexual
transmission of HIV, and therefore justifies future evaluations.
2.4. Material Cytotoxicity
To study cell toxicity, the materials were incubated in culture media at 37 ◦C and 5% CO2 for 48 h
before the assay to ensure that any potential toxic component would be present in the dilutions to
be tested. The cell culture was then treated with a suspension of base 5 serial dilutions of the most
concentrated suspension (1000 µg/mL). Experiments were performed in lymphoblastic (MT-2) and
macrophage-monocyte (THP-1) derived cell lines to evaluate toxicity on the immune cells present in
vaginal or uterine mucosae, and in a uterine epithelial cell line (HEC-1A) to evaluate the potential
damage to mucosal integrity (Figure 12).
As shown in Figure 12 and Table 3, lactic acid and ES100 were biocompatible in the three cell types,
displaying CC50 values of over 1000 µg/mL, the maximum concentration tested. Citric acid CC50 value
in THP-1 was around 1000 µg/mL, which is high enough to rule out a toxic effect in vivo, since it must
pass through the epithelium layers at that concentration to reach the monocytes/macrophages that are
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only present on the inside of the epithelium. The same can be said of TEC since its CC50 of around
1000 µg/mL is only seen in MT-2 cells, which is a lymphocyte type cell line. The only compound
showing cell toxicity below 1000 µg/mL was tartaric acid, with a CC50 of around 200 µg/mL in HEC-1A
cells, with no effect on THP-1 and MT-2 cells. In this case tartaric acid is toxic to the epithelium cells,
which could lead to the disruption of the layer and to a potential inflammatory response, facilitating
viral entry through the vaginal mucosa, as other substances as nonoxynol-9 have been found to do [56].
Therefore, although the concentration needed to obtain the toxic effect is quite high (200 µg/mL), tartaric
acid should be avoided in any formulation to be applied to the vaginal and/or uterine epithelium.
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3. Materials and Methods
3.1. Materials
Tenofovir (TFV, lot: FT104801401, MW: 287.21 g/mol, purity ≥ 98%) was provided by Carbosynth
Limited (Berkshire, UK). Low molecular weight chitosan [18] (CH, lot: 0055790, MW ≈ 32KDa,
purity ≥ 90%) was supplied by Guinama (Valencia, Spain). L(+)-Lactic acid (lot: 0001552193, MW:
90.08 g/mol, purity = 90.8%) was purchased from PanReac AppliChem (Barcelona, Spain). L(+)-Tartaric
acid (lot: BCBW8050, MW: 150.09 g/mol, purity = 99.97%), citric acid (lot: BCBV9045, MW: 192.12 g/mol,
purity ≥ 99.5%) and triethylcitrate (TEC, Lot: BCBN8745V, MW: 276.28 g/mol, purity = 99.9%)
were supplied by Sigma Aldrich (Saint Louis, MO, USA). Eudragit® S100 (ES100, lot: B071005090,
MW = 135KDa [57]) was a kind gift from Evonik (Darmstadt, Germany). All other reagents used in
this study were of analytical grade and used without further purification. Demineralized water was
used in all cases.
3.2. Methods
3.2.1. Manufacture and Characterization of Chitosan Gels
Diluted acids must be used to obtain chitosan gels in aqueous media [54]. 50 mL of chitosan gels
were therefore prepared with three different organic acids (lactic acid, tartaric acid and citric acid) at
three concentrations, as shown in Table 4. The gels obtained were stored for 24 h at room temperature
to ensure the correct hydration of the polymer, then immediately evaluated.
Table 4. Composition of the chitosan gels.
Batch Chitosan (%) Lactic Acid (M) Tartaric Acid (M) Citric Acid (M)
gChL-a 3 0.25
gChL-b 3 0.5
gChL-c 3 1
gChT-a 3 0.25
gChT-b 3 0.5
gChT-c 3 1
gChC-a 3 0.25
gChC-b 3 0.5
gChC-c 3 1
The influence of the acid used and its concentration on the chitosan gels was studied by evaluating
their textural properties with a TA.XTplus Texture Analyser (Stable Micro Systems, Surrey, UK) using
a 5 kg load cell, and following a previously described method [54]. A 20 mm-diameter stainless-steel
probe with an activation force of 2 g was introduced in each gel at a rate of 0.5 mm/s to a depth of 15 mm,
and returned to the initial height at the same rate. 500 points per second were monitored during data
collection, and the maximum penetration force (MPF)—an accurate prediction of gel consistency—was
calculated. The maximum detachment force (MDF), said to be a predictor of adhesive performance,
was also recorded. The test was performed in triplicate for all the gels evaluated.
The pH of the gels was also determined using a pH-meter (GLP 21, Crison Instruments® S.A.,
Barcelona, Spain).
3.2.2. Chitosan Derivative-Based Films
Film Manufacture
Films were obtained from 5 mL of the previously prepared and evaluated gels using the solvent
casting method [9] (Table 5) in silicon moulds. Once the solvent was completely dried at room
temperature, 45-mm diameter circular films were stored until further analysis.
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Table 5. Composition of the chitosan derivative films manufactured with the solvent casting method.
Batch Chitosan (mg) Lactic Acid (mg) Tartaric Acid (mg) Citric Acid (mg) TFV (mg)
ChL-a 150 112.5 (0.25 M)
ChL-b 150 225 (0.5 M)
ChL-c 150 450 (1 M)
ChT-a 150 187.5 (0.25 M)
ChT-b 150 375 (0.5 M)
ChT-c 150 750 (1 M)
ChC-a 150 240 (0.25 M)
ChC-b 150 480 (0.5 M)
ChC-c 150 960 (1 M)
ChL-TFV 150 225 (0.5 M) 30
ChT-TFV 150 375 (0.5 M) 30
ChC-TFV 150 480 (0.5 M) 30
The films were visually assessed to determine the optimum concentration of the different acids
to obtain films based on chitosan derivatives. Their organoleptic properties were observed and their
pliability was determined by folding the films, considering their capacity to deform and recover their
form. The optimal proportions were then prepared using the same method with the addition of 30 mg
of TFV to the gel. The amount of TFV for the development of the films was carefully selected according
to literature and previous evaluations. Among the different dosage forms for the vaginal administration
of this drug in clinical trials, lower and higher doses have been tested, showing adequate efficacy and
security [7]. It has also been proved that extremely low cervicovaginal fluid concentration of TFV
(1000 ng/mL) confer protection against HIV in women, ensuring the efficacy of these films during the
release period [58]. As for the security of the films, it was confirmed in cytotoxicity studies that the
dose included is not toxic for the vaginal tissue [59].
Attenuated Total Reflection Fourier Transform Infrared (FTIR-ATR) Spectroscopy
Attenuated total reflection Fourier transform infrared (FTIR-ATR) spectroscopy was used to
characterize raw materials and chitosan derivative-based films with a Perkin-Elmer spectrophotometer,
equipped with a MIRacle™ accessory designed for measurements (Perkin-Elmer). 16 scans were
recorded for all the spectra at a resolution of 4 cm−1.
Drug Release
Drug release was evaluated following the method described by Sánchez-Sánchez et al. [60].
Each sample was inserted in a borosilicate glass bottle with a 45 mm diameter base containing 80 mL
of SVF and then placed in a shaking water bath (37 ◦C, 15 opm). Samples were taken every hour until
the release of TFV was completed. 5 mL aliquots were removed and filtered, and the medium was
replaced with the same volume of SVF at the same temperature. TFV concentrations were quantified
by UV spectroscopy at a wavelength of 260 nm (AbsSVF = 482.05·C(mg/mL)−0.0019; r2 = 0.9996)
in an Evolution 60S spectrophotometer (Thermo Scientific, Kyoto, Japan). The test was performed
in triplicate.
3.2.3. Layer-by-Layer Films
Manufacture
Although the chitosan derivative-based films had an acceptable texture, they appear unable to
sufficiently modulate the release of the drug. The optimal proportions of each chitosan derivative-based
film were selected to prepare LbL films, adding different proportions of ES100 to prepare the second
layer (Table 6). Since ES100 is an acidic polymer, the interaction between the surface of the chitosan film
and the film based on ES100 occurs through electrostatic interactions, and both layers become tightly
joined. These systems were obtained using the solvent casting method. First, chitosan derivative-based
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films containing TFV were prepared according to the method described above, then after the complete
evaporation of water, a solution of ES100 in 10 mL acetone was added with TEC as a plasticizer.
When this solvent was completely dry at room temperature, the resulting films were stored until
further assessment.
Table 6. Composition of the LbL films manufactured with the solvent casting method.
ChL/E-a ChL/E-b ChT/E-a ChT/E-b ChC/E-a ChC/E-b
CHITOSAN
DERIVATIVE-BASED
LAYER
Chitosan (mg) 150 150 150 150 150 150
Lactic acid (mg) 225 225
Tartaric acid (mg) 375 375
Citric acid (mg) 480 480
Tenofovir (mg) 30 30 30 30 30 30
EUDRAGIT®
S100-BASED LAYER
Eudragit® S100 (mg) 75 150 75 150 75 150
Triethylcitrate (mg) 37.5 75 37.5 75 37.5 75
SEM Microscopy
To verify the structure of the film and the arrangement of the layers, the cross-sections of the
films were analysed by electron microscopy using a field emission scanning electron microscope (JEOL
JSM-6335F, Tokyo, Japan) at an accelerating voltage of 20 V and a work distance of 15 mm.
Texture Analysis
Although the pliability of the chitosan derivative-based films has already been assessed,
the incorporation of the ES100-based layer may lead to a significant modification in the mechanical
properties of the system. The texture of the LbL films was therefore evaluated according to a previously
set up methodology [61] using a TA.XTplus Texture Analyser (Stable Micro Systems, Surrey, UK) with
a 30 kg load cell. Before starting the experiments, each film was fixed to a support rig. A 5mm-diameter
spherical stainless probe with an activation force of 5 g applied increasing force to each film to
maintain a moving rate of 0.5 mm/s. 500 points per second were monitored during data collection,
and the force applied (N) and the distance travelled by the probe (mm) were registered at each point.
The measurement ended when the film burst at the maximum registered force. The distance travelled
by the probe at the burst of the films was also recorded. The deformability of the systems was then
determined as the average distance travelled by the probe when applying a force of 1 N.
All assays were performed in quadruplicate, and the data were statistically processed using
two-way ANOVA (p-value 0.05) with the nature of the chitosan derivative and the proportion of ES100
as factors.
Swelling Behaviour
Swelling studies were performed on the LbL films to characterize the swelling of the formulations
in SVF as a function of time.
The swelling processes of the different batches in SVF were analysed following the method
described by Mamani et al. [62]. Fragments of each formulation with a diameter of 3 cm were fixed
with cyanoacrylate adhesive to stainless steel discs of the same size, with the chitosan derivative-based
layer facing the disc and the ES100 layer facing outwards, thus reproducing the expected conditions
after administration. They were then placed in beakers containing 100 mL of SVF and introduced in
a shaking water bath (37 ◦C, 15 opm). At given times (every hour during the first six hours and once
a day up to constant weight), the discs were extracted from the medium and weighed after removing
excess liquid. Swelling ratio (SR) was calculated according to Equation (1):
SR (%) = [(Fs − Fd)/(Fd·SF)]·100, (1)
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where Fs and Fd correspond to the swollen and dry film weights respectively, and SF represents the
swellable fraction of the film. All the assays were performed in triplicate.
Ex Vivo Mucoadhesion
The mucoadhesion force and work were assessed ex vivo using the TA.XTplus Texture Analyser
(Stable Micro Systems) to check whether the formulations show sufficient mucoadhesion capacity
to adhere to the vaginal mucosa at the time of administration, using a modification of a previously
described method [17]. A 2 × 2 cm fragment of excised bovine vaginal mucosa (obtained from a local
slaughterhouse) was fixed to the bottom of a Petri dish and hydrated with 5 mL of SVF. The LbL
film was fixed to a 1 cm-diameter cylindrical probe, with the chitosan derivative layer facing the
vaginal mucosa, as expected at the time of administration. The preparation was moved at a speed of
1 mm/s until it came into contact with the vaginal mucosa, applying a contact force of 500 g for 30 s.
The probe was then separated from the sample at a speed of 1 mm/s up to the starting height of the test.
The maximum force required to separate the film from the vaginal mucosa (detachment force) was
recorded as the mucosal adhesiveness. The area under the curve between the force-distance profiles
(detachment work) was determined, which is considered to be the mucosal stickiness. Each batch was
evaluated in triplicate.
Drug Release
To verify that the release of TFV from the films is pH dependent, the drug release from the LbL
films was evaluated in SVF (pH = 4.2) and in a SVF and simulated seminal fluid mixture (SVF/SSF, ratio
1:4, pH = 7.5 [63]) to reproduce the conditions after ejaculation during intercourse. Each sample was
inserted in a borosilicate glass bottle with a 45-mm diameter base containing 80 mL of medium, with
the hydrophilic layer of the film in contact with the glass and the hydrophobic layer in contact with the
medium, as it would be positioned in the vagina. The preparation was then placed in a shaking water
bath (37 ◦C, 15 opm). Samples were taken every hour during the first six hours and every day after
that at given times. 5mL aliquots were removed and filtered, and the medium was replaced with the
same volume of either SVF or SVF/SSF at the same temperature. TFV concentrations were quantified
by UV spectroscopy at a wavelength of 260nm (AbsSVF/SSF = 482.23·C(mg/mL)−0.0145; r2 = 0.9990)
in an Evolution 60S spectrophotometer (Thermo Scientific, Kyoto, Japan). The test was performed
in triplicate.
The release profiles of the LbL films were compared using a f2 statistic [64] in order to determine
whether there are significant differences between the two media, and whether the thickness of the
ES100 layer determines the release of the drug.
3.2.4. Material Cytotoxicity
Three human cell lines were used: a lymphoblastic cell line, MT-2 [65], a macrophage-monocyte
derived cell line, THP-1 (ATCC® TIB-202) and a uterine/endometrial epithelial cell line, HEC-1A
(ATCC® HTB-112™) (kindly provided by Maria Angeles Muñoz). All the cell lines were cultured in
RPMI 1640 medium supplemented with 10 % (v/v) fetal bovine serum, 2 mM L-glutamine and 50 mg/mL
streptomycin (all Whittaker M.A. Bio-Products, Walkerville, MD, USA) at 37 ◦C in a humidified
atmosphere of 5 % CO2. To detach the HEC-1-A cells, the medium was removed and the flask was
rinsed during 10 min with 1 to 2 mL of trypsin 0.25%—EDTA 0.03% solution. The medium was
replaced every three days after cell centrifugation at 1500 rpm for 5 min.
Cell toxicity was measured using the CellTiter Glo kit (Promega, Madison, WI, USA). Cells were
incubated in 96-well plates at a density of 10 × 105 cells per well (MT-2 and THP-1) and 2 × 104
(HEC-1A) in complete medium. To assess the cytotoxic effect, cells were exposed to fresh medium
containing different concentrations of lactic acid, tartaric acid, citric acid, TEC and ES100 suspensions,
or the same concentration of PBS 1× as control. Experiments were performed in triplicate and the
culture was maintained at 37 ◦C and 5% CO2 humidified atmosphere for 48 h. A standard method was
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followed to suspend the materials in PBS 1× [66]. After incubation for 48 h, the medium was removed
from cell cultures and 50 µL of CellTiter Glo reactive was added to each well on the plate. Relative
luminescence units (RLUs) were measured in a luminometer (Sirius, Berthold Detection Systems).
Cytotoxic concentration 50 (CC50) values were calculated using GraphPad Prism Software (non-linear
regression, log inhibitor versus response). The results of the cytotoxic assay are shown as the average
of at least three individual experiments.
4. Conclusions
The gelation of chitosan in different diluted acids allows the production of chitosan derivative-based
films with different mechanical properties without the need to include plasticizers. It has been
confirmed that the crosslinking of the chitosan chains with tartaric acid or citric acid generates films
with improved mechanical properties. The combination of these films with a polymer with pH-sensitive
solubility (Eudragit® S100) produces formulations that exhibit a pH-dependant Tenofovir release, high
mucoadhesion, and a moderate swelling profile, which would make them comfortable for the patient.
Among the films obtained through the layer-by-layer technique, those based on the combination
of chitosan citrate and Eudragit® S100 in a 1:1 ratio (ChC/E-b) allow a sustained release of Tenofovir
for up to five days in simulated vaginal fluid and release all the drug in less than 4 h after sexual
intercourse, with very moderate swelling and a high mucoadhesion capacity. The materials used
were also non-toxic in the vaginal environment. These formulations are thus a future option for the
prevention of the sexual transmission of HIV in women.
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